Compare IMTE & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMTE | PFSA |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 1.7M |
| IPO Year | 2016 | N/A |
| Metric | IMTE | PFSA |
|---|---|---|
| Price | $0.50 | $0.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.2K | ★ 167.6K |
| Earning Date | 10-22-2024 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.40 | $0.05 |
| 52 Week High | $1.54 | $4.22 |
| Indicator | IMTE | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 45.21 | 27.37 |
| Support Level | $0.51 | $0.07 |
| Resistance Level | $0.57 | $0.41 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 72.50 | 4.91 |
Integrated Media Technology Ltd is mainly engaged in the business of manufacture and sale of nano-coated plates for filters, the manufacture and sale of electronic glass, Halal certification and distribution of Halal products, and new energy products and services. It operates through the following segments: the sale of electronic glass, sales of air-filter products, sales of Halal products, NFT, corporate, provision of consultancy and provision of new energy products and solutions.
Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.